Skip to content
OpenCapital
Get started

Artiva Biotherapeutics, Inc. ARTV Q2 2025 earnings

Reported August 6, 2025 · Before market open

Revenue-Diluted EPS-$0.87Miss by $0.03
EPS estimate-$0.84

Next report

Aug 5, 2026 (in a month)
EPS estimate-$0.64

Financials

Q2 2025

Income statement

See full
Revenue-—
Operating income-$22.8M-40.9%
Net income-$21.3M-19.1%
EPS (diluted)-$0.87+96.0%

Balance sheet

See full
Cash & equivalents$28.9M-16.2%
Total debt$13.2M-16.1%
Total equity$149.0M+178%
Total assets$169.4M+123%

Cash flow

See full
Operating cash flow-$23.0M-67.9%
CapEx$1.1M+127%
Free cash flow-$24.0M-69.9%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$39.22M—
Enterprise value$23.52M—

Returns & leverage

See full
Debt / equity0.1×—
Current ratio13.8×+9.2×

Versus estimates

Diluted EPS

Q1 2026-$0.95Miss by $0.07Q4 2025-$0.84Beat by $0.03Q3 2025-$0.88Beat by $0.04
Q2 2025-$0.87Miss by $0.03
Q1 2025-$0.83Miss by $0.15Q4 2024-$0.66Beat by $0.05

Ask the moment Artiva Biotherapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Artiva Biotherapeutics, Inc. report Q2 2025 earnings?
Artiva Biotherapeutics, Inc. (ARTV) reported Q2 2025 earnings on August 6, 2025 before market open.
What were Artiva Biotherapeutics, Inc.'s Q2 2025 revenue and EPS?
Artiva Biotherapeutics, Inc. reported revenue of - and diluted EPS of $-0.87 for Q2 2025.
Did Artiva Biotherapeutics, Inc. beat estimates in Q2 2025?
EPS missed the consensus estimate of $-0.84 by $0.03.
How did Artiva Biotherapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 39.3% from $-0.62.
Where can I find Artiva Biotherapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0000950170-25-104045) directly on SEC EDGAR. The filing index links above go to sec.gov.